SOURCE: Calmune Corporation

Calmune Corporation

November 03, 2009 03:00 ET

Calmune and Crucell Enter Exclusive Research Collaboration

Calmune to Use Proprietary Technology Platform to Generate Potent Human Monoclonal Antibodies Against Infectious Diseases

SAN DIEGO, CA--(Marketwire - November 3, 2009) - Calmune Corporation, a privately held biotechnology company developing novel antibodies to address unmet clinical needs, announced today that it has established an exclusive research collaboration with Crucell N.V. (EURONEXT: CRXL) (NASDAQ: CRXL) (SWISS: CRX), a global biopharmaceutical company based in Leiden, the Netherlands, focusing on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases. Financial details of the agreement were not disclosed.

Under this collaboration, Calmune will use SEBVI™, a proprietary technology to prepare a panel of potent, high-affinity human monoclonal antibodies (hMabs) against a pre-defined, undisclosed infectious disease target. Crucell will have the option to exclusively license these hMabs for further evaluation as development candidates, and to develop any that meet its required profile. Calmune will receive payments from Crucell at different stages of the discovery and development process, as well as a royalty on sales of products that incorporate antibodies generated by Calmune.

By exploiting the power of the human immune response, Calmune's SEBVI™ technology allows natural, high-affinity, fully human antibodies against microbial targets to be efficiently recovered from Epstein Barr virus-transformed memory B cells.

Dr. Jaap Goudsmit, Chief Scientific Officer of Crucell, said, "Calmune's demonstrated technological expertise in the generation of potent human monoclonal antibodies is a valuable complement to Crucell's existing research programs and opens the door to the development of new therapeutics for infectious diseases."

Dr. Anthony Williamson, CEO of Calmune, and Dr. Dennis Burton, Chairman of the Board, commented in a joint statement, "We are delighted to be working together with Crucell, which has an established commitment to developing and marketing therapeutic antibodies against infectious diseases. This collaboration is an important external endorsement of our technology, and we are confident we will be able to deliver candidate antibodies that meet Crucell's requirements. We would like to gratefully acknowledge the support of Tilocor, our principal investor, towards Calmune's emergence as an innovative therapeutic antibody company."

About Calmune

Calmune Corporation is a privately held biotechnology company developing antibody therapeutics to address unmet clinical needs. The company was founded in 2006 in San Diego, California, by three members of The Scripps Research Institute. Calmune has two novel technology platforms that provide a rapid means to recover high affinity, fully-human antibodies, and to create novel antibodies with unique structural modifications for targeting hypoimmunogenic epitopes. Calmune has received financing from its principal investor, Tilocor Life Science. Calmune has a growing pipeline of early-stage product candidates in several therapeutic areas. For more information, please see

About Tilocor Life Science

Tilocor Life Science provides financial support for the Tilocor Group's newly created companies, acquisitions and investments. Co-founded by Professor Stefan Catsicas, former Vice-President of the Swiss Federal Institute of Technology (Lausanne), Tilocor promotes an entrepreneurial approach adapted to the long-term needs of the life science sector. Currently, Tilocor companies focus on infectious diseases, inflammation and cancer with specific therapeutic agents that include human antibodies, intracellular peptides and small chemical entities.

About Crucell

Crucell N.V. (EURONEXT: CRXL) (NASDAQ: CRXL) (SWISS: CRX) is a global biopharmaceutical company focused on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several product candidates based on its unique PER.C6® production technology. The Company licenses its PER.C6® technology and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi-aventis, Novartis, Wyeth, GSK, CSL and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea, UK and the U.S. The Company employs over 1200 people. For more information, please visit

Contact Information

  • For further information pertaining to Calmune, please contact:

    Anthony Williamson
    Chief Executive Officer
    T. +1 858 657 0283
    Email Contact

    Dynamics Group
    Christophe Lamps
    T. +41 22 308 62 22
    M. +41 79 476 26 87
    Email Contact

    For US media
    Linnden Communications
    Michelle Linn
    T. +1 508-362-3087
    M. +1 774-696-3803
    Email Contact